Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

35 results about "Molecular virology" patented technology

Molecular virology is the study of viruses on a molecular level. Viruses are submicroscopic parasites that replicate inside host cells. They are able to successfully infect and parasitize all kinds of life forms- from microorganisms to plants and animals- and as a result viruses have more biological diversity than the rest of the bacterial, plant, and animal kingdoms combined. Studying this diversity is the key to a better understanding of how viruses interact with their hosts, replicate inside them, and cause diseases.

Monoclonal antibody of Japanese encephalitis virus and Zika virus and application thereof

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and relates to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises a VH CDR1, a VH CDR2 and a VH CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and a VL CDR1, a VL CDR2 and a VL CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 4-6. A large number of experimental studies show that the monoclonal antibody can specifically recognize and target extracellular regions of E proteins of the Japanese encephalitis virus and the Zika virus, can block combination of the E proteins and cell surface receptors, and shows efficient virus neutralizing capacity. Therefore, the antibody provided by the invention is particularly suitable for being used for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.
Owner:NINGBO UNIV

Antibody for recognizing RSV pre-f protein and use thereof

The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and / or treatment of RSV infection and / or diseases caused by the infections.
Owner:XIAMEN UNIV

Truncated varicella-zoster virus envelope glycoprotein ge

The present invention relates to the field of immunology and the field of molecular virology, in particular to the field of prevention and treatment of varicella-zoster viruses. Specifically, the present invention relates to a truncated varicella-zoster virus gE protein (or a variant thereof) capable of be soluble expression in an Escherichia coli expression system, and use thereof in preventing and / or treating varicella-zoster virus infections.
Owner:XIAMEN UNIV +1

Modified modaria virus, self-replicating RNA constructs and uses thereof

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising a modified viral genome or self-replicating RNA, pharmaceutical compositions containing said nucleic acid molecules, and the use of such nucleic acid molecules and compositions for producing a desired product in a cell culture or in vivo. Also provided are methods for eliciting a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating a variety of health conditions.
Owner:REPLICATE BIOSCIENCE INC

Modified alphaviruses with heterologous nonstructural proteins

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons (e.g., self-replicating RNAs), pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and / or treating various health conditions.
Owner:REPLICATE BIOSCIENCE INC

Antibodies that recognize RSV pre-F protein and uses thereof

summary The present invention relates to the field of immunology and molecular virology, in particular to the field of prevention and treatment of RSV, specifically to a monoclonal antibody capable of specifically binding to a new epitope between the Φ epitope and the V epitope on the pre-F protein, or between the II epitope and the V epitope, and its use in the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection.
Owner:XIAMEN UNIV

Modified western equine encephalitis viruses and uses thereof

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or self-replicating RNAs, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions.
Owner:REPLICATE BIOSCIENCE INC

Anti-RSV pre-F protein antibody and application thereof

The invention relates to the fields of immunology and molecular virology, in particular to the fields of prevention and treatment of RSV (Respiratory Syndrome Virus). Specifically, the invention provides a monoclonal antibody capable of specifically binding to a neoepitope on pre-F protein, and application of the monoclonal antibody to detection, prevention and / or treatment of RSV infection and / or diseases caused by the infection.
Owner:XIAMEN UNIV +1

Compositions and methods for preventing and treating rabies virus infections

The present disclosure relates generally to the field of molecular virology, and in particular to nucleic acid molecules encoding modified alphavirus viral genomes or self-replicating RNA (srRNA) constructs, recombinant cells and pharmaceutical compositions containing the same, and the use of such nucleic acid molecules, recombinant cells, and compositions to produce desired products in cell culture or in vivo. Also provided are methods for inducing an immune response in a subject in need thereof, and methods for preventing and / or treating rabies virus infection.
Owner:リプリケイト バイオサイエンスインコーポレイティド

Broad spectrum binding monoclonal antibody targeting alpha herpes virus and application thereof

The invention relates to the fields of immunology and molecular virology, in particular to the field of alpha herpes virus diagnosis. Specifically, the invention relates to an anti-alpha herpes virus monoclonal antibody and a kit containing the antibody. In addition, the invention also relates to application of the antibody.
Owner:XIAMEN UNIV

An alpaca-derived nanobody screened by phage display technology that binds to HPV16-L1 protein and its applications

The present invention belongs to the technical fields of molecular virology and immunology, and provides a camelid-derived nanobody screened by phage display technology that binds to the HPV16-L1 protein, with a heavy chain variable region VHH, comprising the following CDRs and FRs: CDR1 shown in SEQ ID NO:1; CDR2 shown in SEQ ID NO:2; CDR3 shown in SEQ ID NO:3; FR1 shown in SEQ ID NO:4; FR2 shown in SEQ ID NO:5; FR3 shown in SEQ ID NO:6; FR4 shown in SEQ ID NO:7. It provides potential new nanobody drugs for the clinical prevention, treatment and detection of human papillomavirus HPV16. It has a small molecular weight, low immunogenicity, high solubility, strong stability, can reach the infection site directly, and takes effect faster, providing a potential treatment strategy for virus infection.
Owner:SHANXI PROVINCE CHINESE MEDICINE RESEARCH INSTITUTE +2

A monoclonal antibody against Japanese encephalitis virus and Zika virus and its application

The present invention discloses a monoclonal antibody against Japanese encephalitis virus and Zika virus and its application, which relates to the technical fields of immunology and molecular virology. The monoclonal antibody or its antigen-binding fragment comprises VH CDR1, VH CDR2 and VH CDR3 with amino acid sequences shown in SEQ ID NO: 1-3, and VL CDR1, VL CDR2 and VL CDR3 with amino acid sequences shown in SEQ ID NO: 4-6. After a large number of experimental studies, the present invention discovers a monoclonal antibody which can specifically recognize and target the extracellular region of the E protein of Japanese encephalitis virus and Zika virus, and can block the binding of the E protein to the cell surface receptor, showing a high ability to neutralize the virus. Therefore, the antibody of the present invention is particularly suitable for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.
Owner:NINGBO UNIV

An alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its application.

PendingCN122302048AHeavy chainChikungunya
This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.
Owner:SHANXI PROVINCE CHINESE MEDICINE RESEARCH INSTITUTE

Monoclonal antibody of Japanese encephalitis virus and Zika virus and application thereof

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and belongs to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises VH CDR1, VH CDR2 and VH CDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VL CDR1 and VL CDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence is VL CDR2 of AAS. The monoclonal antibody LZY2086 provided by the invention can be combined with E protein extracellular regions of the encephalitis B virus and the Zika virus with high affinity, and has very strong neutralizing activity on the encephalitis B virus and the Zika virus. Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody LZY2086 disclosed by the invention has ideal clinical application value in prevention and treatment of Japanese encephalitis virus and Zika virus infection.
Owner:NINGBO CENTER FOR DISEASE CONTROL & PREVENTION (NINGBO HEALTH SUPERVISION INSTITUTE NINGBO HEALTH EDUCATION & PROMOTION CENTER) +1

Primer group for detecting mumps virus, application of primer group, kit and application of kit

The invention relates to the technical field of chemical synthesis and diagnostic reagents, in particular to a primer group for detecting mumps virus, application of the primer group, a kit and application of the kit. The mumps virus NCRs multiplex RT-PCR amplification method is established on the basis of a multiplex PCR principle, one tube for three detections is realized, amplification products of three non-coding regions of N-P, P-M and M-F are obtained through successful amplification, and a full-length sequence of the NCRs is obtained through sequence splicing. Based on the primer group, the invention provides the primer group for detecting the mumps virus NCRs. A gene sequence of mumps virus NCRs is analyzed by a bioinformatics method, and three groups of primers respectively aiming at three non-coding regions of N-P, P-M and M-F are synthesized by a chemical synthesis technology. The primer group provided by the invention can be used for identifying the MuV, can also be used for simultaneously detecting three non-coding region sequences of N-P, P-M and M-F of the MuV, and is used for molecular virology monitoring.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT

Domesticated low-serum Vero cell line and method for preparing HSV (herpes simplex virus) vector through suspension culture cell amplification

The invention relates to neurobiology, molecular virology, biomedical engineering and the like, and discloses a domesticated low-serum Vero cell line and a method for preparing an HSV virus vector through suspension culture cell amplification. Aiming at the bottleneck problem that a process for amplifying HSV by adherent culture of Vero cells is difficult to realize large-scale and engineering amplified production, the invention researches and develops a method for preparing HSV based on suspension culture of cell amplification. Vero cells introduced from ATCC are domesticated, and the serum content of a culture medium is gradually reduced, so that the Vero cells are suitable for suspension culture in a microcarrier or sheet carrier reactor by using a low-serum or serum-free culture medium. The method comprises the following steps: using Tamp of Dibide Bioengineering (Shanghai) Co., Ltd; and carrying out suspension culture of the Vero cells and infection amplification of the HSV virus vector by using a J Cloud Ready TM bioreactor. High-activity suspension culture and HSV amplification of Vero cells are realized by optimizing production conditions, cell density, biochemical detection and the like, and a stable and efficient method is provided for preparing a high-titer and high-purity HSV virus vector in combination with purification process upgrading.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Monoclonal antibody against novel coronavirus and application thereof

The present document relates to the field of immunology and the field of molecular virology, in particular the field of diagnosis, prevention and treatment of the novel coronavirus. In particular, the present document relates to monoclonal antibodies against the novel coronavirus, as well as compositions (e.g. diagnostic and therapeutic agents) comprising said antibodies. Furthermore, the present document also relates to uses of said antibodies. The antibodies described herein can be used for the diagnosis, prevention and / or treatment of an infection with the novel coronavirus and / or a disease caused by said infection (e.g. COVID-19).
Owner:PEKING UNIV

Compositions and methods for inducing ESR1, PI3k, her2, and her3 immune responses

The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and / or treating cancer.
Owner:REPLICATE BIOSCIENCE INC

Antibodies recognizing rsv pre-f protein and uses

The present invention relates to the field of immunology and molecular virology, in particular the field of prevention and treatment of RSV. In particular, the present invention provides monoclonal antibodies capable of specifically binding to a new epitope between the pre-F protein and the V epitope or a new epitope between the II and the V epitope, and their use for the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection.
Owner:XIAMEN UNIV

Single domain antibodies against SARS-CoV-2 and their uses

The present invention relates to the fields of immunology and molecular virology, in particular to the diagnosis, prevention and treatment of coronaviruses (e.g., SARS-CoV-2). Specifically, the present invention relates to single-domain antibodies against coronaviruses, and uses of the single-domain antibodies. The antibodies of the present invention can be used to diagnose, prevent and / or treat coronavirus infections and / or diseases caused by the infections.
Owner:XIAMEN UNIV +1

Antibodies against sars-cov-2 and uses thereof

The present invention relates to the field of immunology and the field of molecular virology, in particular the field of diagnosis, prevention and treatment of SARS-CoV-2. In particular, the present invention relates to monoclonal antibodies against SARS-CoV-2, and compositions (e.g., diagnostic and therapeutic agents) comprising said antibodies. Furthermore, the present invention also relates to uses of said antibodies. The antibodies of the present invention can be used for the diagnosis, prevention and / or treatment of SARS-CoV-2 infection and / or a disease caused by said infection (e.g., COVID-19).
Owner:YANG SHENG TANG +1

Modified western equine encephalitis virus and uses thereof

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising a modified viral genome or self-replicating RNA, pharmaceutical compositions containing said nucleic acid molecules, and the use of such nucleic acid molecules and compositions for producing a desired product in a cell culture or in vivo. Also provided are methods for eliciting a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating a variety of health conditions.
Owner:REPLICATE BIOSCIENCE INC

Epitope peptide and antibody for treating HBV infection and related diseases

The present invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection treatment. In particular, the present invention relates to an epitope peptide (or a variant thereof) capable of treating a hepatitis B virus infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and an antibody (e.g. a nanobody) for the epitope peptide. The epitope peptide and antibody of the present invention can be used to prevent and / or treat HBV infection or a disease related to HBV infection (e.g. hepatitis B), for reducing the serum level of HBV DNA and / or HBsAg in a subject (e.g. a human), or for activating a subject (e.g. a chronic HBV infected person or a chronic hepatitis B patient) against HBV humoral immune response.
Owner:XIAMEN UNIV +1

Modified madagascar viruses, self-replicating RNA constructs, and uses thereof

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or self-replicating RNA, pharmaceutical compositions comprising the same, and the use of such nucleic acid molecules and compositions to produce desired products in cell culture or in an organism. Methods for inducing a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions, are also provided.
Owner:リプリケイト バイオサイエンスインコーポレイティド

Compositions and methods for the prevention and treatment of rabies virus infection

The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and / or treating rabies virus infection.
Owner:REPLICATE BIOSCIENCE INC

Databa virus circular RNA and application thereof in preparation of vaccine

The invention discloses a circular RNA (Ribose Nucleic Acid) of a Databan virus and an application of the circular RNA in preparation of vaccines, and belongs to the technical field of immunology and molecular virology. The sequence of the circular RNA of the large allofanda virus is formed by connecting a sequence shown in SEQ ID NO.2 end to end. After cells are transfected by the circular RNA of the Databu virus, virus-like particles of the Databu virus can be generated. After the circular RNA is encapsulated by the lipid nanoparticles, an immunized mouse can induce a high-level megabo virus neutralizing antibody and T cell immunity, and the immunized mouse serum can protect the mouse from being attacked by a lethal megabo virus. The invention provides a theoretical basis for further developing a safer, more efficient and quicker circular RNA vaccine for the GABA virus.
Owner:NINGBO UNIV

TCR-like antibodies for diagnosis and treatment of hepatitis b virus infection

The invention relates to the field of molecular virology and immunology, in particular to the field of hepatitis B virus (HBV) infection. In particular, the present invention relates to TCR-like antibodies and multispecific antibodies for the treatment of Hepatitis B virus (HBV) infection, such as Chronic Hepatitis B (CHB), and their use in the diagnosis and treatment of disease.
Owner:XIAMEN UNIV

A human monoclonal antibody against Japanese encephalitis virus and Zika virus and its application

The present invention provides a human monoclonal antibody against Japanese encephalitis virus and Zika virus and its application, belonging to the cross-field of immunology and molecular virology. The monoclonal antibody provided by the present invention includes: CDR1 of the heavy chain variable region shown in SEQ ID No.1, CDR2 of the heavy chain variable region shown in SEQ ID No.2, CDR3 of the heavy chain variable region shown in SEQ ID No.3, CDR1 of the light chain variable region shown in SEQ ID No.4, CDR2 of the light chain variable region shown in SEQ ID No.5, and CDR3 of the light chain variable region shown in SEQ ID No.6. The human monoclonal antibody provided by the present invention can bind to the extracellular region of the E protein of Japanese encephalitis virus and Zika virus with high affinity, and has strong neutralizing activity against Japanese encephalitis virus and Zika virus, and has ideal clinical application value for preventing and treating Japanese encephalitis virus and Zika virus infections.
Owner:NINGBO UNIV

Compositions and methods for preventing and treating rabies virus infection

The present disclosure generally relates to the field of molecular virology, the present invention relates to nucleic acid molecules, and in particular to nucleic acid molecules encoding modified alphavirus viral genomes or self-replicating RNA (srRNA) constructs, recombinant cells and pharmaceutical compositions containing said nucleic acid molecules and the use of such nucleic acid molecules, recombinant cells and compositions for producing desired products in cell cultures or in vivo. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and / or treating a rabies virus infection.
Owner:REPLICATE BIOSCIENCE INC

Antibodies to SARS-CoV-2 and its mutants and their applications

The present application relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of SARS-CoV-2 and its mutants. Specifically, the present application relates to antibodies or antigen-binding fragments against SARS-CoV-2 and its mutants, and compositions (e.g., diagnostic agents and therapeutic agents) comprising the antibodies. In addition, the present application also relates to the use of the antibodies or antigen-binding fragments. The antibodies or antigen-binding fragments of the present application can be used to diagnose, prevent and / or treat SARS-CoV-2 and its mutants infection and / or diseases caused by the infection.
Owner:XINXIANG MEDICAL UNIV